ANVS Jan 2025 15.000 call
| Previous close | 1.2500 |
| Open | 0.7000 |
| Bid | 0.4000 |
| Ask | 1.2500 |
| Strike | 15.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.7000 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 52 |
ZacksMerck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
ZacksCASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
GlobeNewswireAnnovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announced today the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap. This patent encompasses the methods for manufacturing the new crystalline form of bunta
